Industry Roundup: Align Litigation Proceeds, FTC Ices Pure Green Coffee, Supplement Warning
This article was originally published in The Tan Sheet
Supreme Court denies P&G petition; plug pulled on Pure Green Coffee; and another own-label supplement distributor warned.
You may also be interested in...
FTC says Pure Green Coffee perks false claims; NBTY shareholder settles insider trading case; scientific citations trigger warning letter; supplement labels must detail plant source; scientific citations trigger warning; and more news In Brief.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.